Cargando…

Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?

BACKGROUND: New data indicates that vancomycin may be less effective against methicillin-resistant Staphylococcus aureus (MRSA) infections with minimum inhibition concentration (MIC) within a sensitive range. OBJECTIVES: The aim of this study was to determine the distribution of the vancomycin MIC b...

Descripción completa

Detalles Bibliográficos
Autores principales: Aminzadeh, Zohreh, Yadegarynia, Davood, Fatemi, Alireza, Tahmasebian Dehkordi, Elham, Azad Armaki, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295319/
https://www.ncbi.nlm.nih.gov/pubmed/25632329
http://dx.doi.org/10.5812/jjm.12831
_version_ 1782352825334890496
author Aminzadeh, Zohreh
Yadegarynia, Davood
Fatemi, Alireza
Tahmasebian Dehkordi, Elham
Azad Armaki, Saeed
author_facet Aminzadeh, Zohreh
Yadegarynia, Davood
Fatemi, Alireza
Tahmasebian Dehkordi, Elham
Azad Armaki, Saeed
author_sort Aminzadeh, Zohreh
collection PubMed
description BACKGROUND: New data indicates that vancomycin may be less effective against methicillin-resistant Staphylococcus aureus (MRSA) infections with minimum inhibition concentration (MIC) within a sensitive range. OBJECTIVES: The aim of this study was to determine the distribution of the vancomycin MIC between MRSA strains and observe the difference in mortality between patients, while the influence of changes in MIC on the efficacy of vancomycin was also examined. PATIENTS AND METHODS: A routine date-based study was conducted on 41 MRSA isolates in a hospital in Tehran, Iran. The isolates were assessed for MIC by using the E-test method, and results were categorized into three groups: A (MIC < 1.5 μg/mL), B (1.5 ≤ MIC < 2 μg/mL) and C (MIC ≥ 2 μg/mL) MRSA. RESULTS: Group A was the most common group, followed by groups C and B. Although there was no statistically significant difference between patients’ mortality with the MIC group, the mortality rate of group A was higher than C and B. CONCLUSIONS: Regarding Clinical and Laboratory Standards Institute (CLSI) definition for vancomycin susceptibility (MIC < 2 μg/mL), it seems that vancomycin may not be considered as the best antibiotic in order to treat heteroresistant vancomycin intermediate S. aureus (hVISA) and vancomycin sensitive S. aureus (VSSA) infections, and a new breakpoint for vancomycin and alternative antibiotics should be considered.
format Online
Article
Text
id pubmed-4295319
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-42953192015-01-28 Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients? Aminzadeh, Zohreh Yadegarynia, Davood Fatemi, Alireza Tahmasebian Dehkordi, Elham Azad Armaki, Saeed Jundishapur J Microbiol Brief Report BACKGROUND: New data indicates that vancomycin may be less effective against methicillin-resistant Staphylococcus aureus (MRSA) infections with minimum inhibition concentration (MIC) within a sensitive range. OBJECTIVES: The aim of this study was to determine the distribution of the vancomycin MIC between MRSA strains and observe the difference in mortality between patients, while the influence of changes in MIC on the efficacy of vancomycin was also examined. PATIENTS AND METHODS: A routine date-based study was conducted on 41 MRSA isolates in a hospital in Tehran, Iran. The isolates were assessed for MIC by using the E-test method, and results were categorized into three groups: A (MIC < 1.5 μg/mL), B (1.5 ≤ MIC < 2 μg/mL) and C (MIC ≥ 2 μg/mL) MRSA. RESULTS: Group A was the most common group, followed by groups C and B. Although there was no statistically significant difference between patients’ mortality with the MIC group, the mortality rate of group A was higher than C and B. CONCLUSIONS: Regarding Clinical and Laboratory Standards Institute (CLSI) definition for vancomycin susceptibility (MIC < 2 μg/mL), it seems that vancomycin may not be considered as the best antibiotic in order to treat heteroresistant vancomycin intermediate S. aureus (hVISA) and vancomycin sensitive S. aureus (VSSA) infections, and a new breakpoint for vancomycin and alternative antibiotics should be considered. Kowsar 2014-10-01 2014-10 /pmc/articles/PMC4295319/ /pubmed/25632329 http://dx.doi.org/10.5812/jjm.12831 Text en Copyright © 2014, Ahvaz Jundishapur University of Medical Sciences; Published by Kowsar Corp. http://creativecommons.org/licenses/by-nc/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Report
Aminzadeh, Zohreh
Yadegarynia, Davood
Fatemi, Alireza
Tahmasebian Dehkordi, Elham
Azad Armaki, Saeed
Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?
title Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?
title_full Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?
title_fullStr Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?
title_full_unstemmed Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?
title_short Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?
title_sort vancomycin minimum inhibitory concentration for methicillin-resistant staphylococcus aureus infections; is there difference in mortality between patients?
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4295319/
https://www.ncbi.nlm.nih.gov/pubmed/25632329
http://dx.doi.org/10.5812/jjm.12831
work_keys_str_mv AT aminzadehzohreh vancomycinminimuminhibitoryconcentrationformethicillinresistantstaphylococcusaureusinfectionsistheredifferenceinmortalitybetweenpatients
AT yadegaryniadavood vancomycinminimuminhibitoryconcentrationformethicillinresistantstaphylococcusaureusinfectionsistheredifferenceinmortalitybetweenpatients
AT fatemialireza vancomycinminimuminhibitoryconcentrationformethicillinresistantstaphylococcusaureusinfectionsistheredifferenceinmortalitybetweenpatients
AT tahmasebiandehkordielham vancomycinminimuminhibitoryconcentrationformethicillinresistantstaphylococcusaureusinfectionsistheredifferenceinmortalitybetweenpatients
AT azadarmakisaeed vancomycinminimuminhibitoryconcentrationformethicillinresistantstaphylococcusaureusinfectionsistheredifferenceinmortalitybetweenpatients